Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: MYCBP2

Gene summary for MYCBP2

Gene summary.

Gene information	Species	Human
	Gene symbol	MYCBP2
	Gene ID	23077
	Gene name	MYC binding protein 2
	Gene Alias	Myc-bp2
	Cytomap	13q22.3
	Gene Type	protein-coding
	GO ID	GO:0000902
	UniProtAcc	O75592

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
23077	MYCBP2	CA_HPV_1	Human	Cervix	CC	7.00e-03	-3.50e-02	0.0264
23077	MYCBP2	N_HPV_2	Human	Cervix	N_HPV	1.09e-02	8.43e-02	-0.0131
23077	MYCBP2	CCI_1	Human	Cervix	CC	5.43e-07	1.10e+00	0.528
23077	MYCBP2	CCI_2	Human	Cervix	CC	3.05e-16	1.55e+00	0.5249
23077	MYCBP2	CCI_3	Human	Cervix	CC	3.17e-11	1.17e+00	0.516
23077	MYCBP2	sample3	Human	Cervix	CC	2.45e-02	9.83e-02	0.1387
23077	MYCBP2	T3	Human	Cervix	CC	4.05e-03	9.99e-02	0.1389
23077	MYCBP2	HTA11_3410_2000001011	Human	Colorectum	AD	5.10e-17	-6.24e-01	0.0155
23077	MYCBP2	HTA11_2487_2000001011	Human	Colorectum	SER	3.63e-06	-5.58e-01	-0.1808
23077	MYCBP2	HTA11_3361_2000001011	Human	Colorectum	AD	3.18e-09	-6.96e-01	-0.1207
23077	MYCBP2	HTA11_83_2000001011	Human	Colorectum	SER	1.85e-03	-5.11e-01	-0.1526
23077	MYCBP2	HTA11_696_2000001011	Human	Colorectum	AD	1.12e-13	-5.17e-01	-0.1464
23077	MYCBP2	HTA11_866_2000001011	Human	Colorectum	AD	1.59e-08	-4.74e-01	-0.1001
23077	MYCBP2	HTA11_5212_2000001011	Human	Colorectum	AD	1.16e-02	-6.35e-01	-0.2061
23077	MYCBP2	HTA11_7862_2000001011	Human	Colorectum	AD	1.48e-02	-4.10e-01	-0.0179
23077	MYCBP2	HTA11_866_3004761011	Human	Colorectum	AD	6.83e-09	-4.58e-01	0.096
23077	MYCBP2	HTA11_10711_2000001011	Human	Colorectum	AD	3.23e-05	-4.54e-01	0.0338
23077	MYCBP2	HTA11_7696_3000711011	Human	Colorectum	AD	9.40e-04	-2.70e-01	0.0674
23077	MYCBP2	HTA11_6818_2000001021	Human	Colorectum	AD	9.20e-04	-4.38e-01	0.0588
23077	MYCBP2	HTA11_99999970781_79442	Human	Colorectum	MSS	4.28e-02	-2.95e-01	0.294

Page: 1 2 3 4 5 6 7 8 9 10 11

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:004851112	Lung	AIS	rhythmic process	61/1849	298/18723	2.63e-08	3.40e-06	61
GO:000762313	Lung	AIS	circadian rhythm	46/1849	210/18723	1.71e-07	1.72e-05	46
GO:003139613	Lung	AIS	regulation of protein ubiquitination	46/1849	210/18723	1.71e-07	1.72e-05	46
GO:003292211	Lung	AIS	circadian regulation of gene expression	21/1849	68/18723	1.33e-06	8.53e-05	21
GO:000989513	Lung	AIS	negative regulation of catabolic process	55/1849	320/18723	3.22e-05	1.01e-03	55
GO:004217713	Lung	AIS	negative regulation of protein catabolic process	26/1849	121/18723	1.09e-04	2.57e-03	26
GO:000740911	Lung	AIS	axonogenesis	64/1849	418/18723	2.62e-04	5.04e-03	64
GO:006156411	Lung	AIS	axon development	69/1849	467/18723	4.37e-04	7.41e-03	69
GO:190332211	Lung	AIS	positive regulation of protein modification by small protein conjugation or removal	25/1849	138/18723	2.05e-03	2.26e-02	25
GO:003139811	Lung	AIS	positive regulation of protein ubiquitination	22/1849	119/18723	2.85e-03	2.84e-02	22
GO:002195511	Lung	AIS	central nervous system neuron axonogenesis	9/1849	35/18723	5.76e-03	4.81e-02	9
GO:004217620	Oral cavity	OSCC	regulation of protein catabolic process	254/7305	391/18723	1.07e-25	3.22e-23	254
GO:190332020	Oral cavity	OSCC	regulation of protein modification by small protein conjugation or removal	165/7305	242/18723	2.52e-20	3.99e-18	165
GO:003139620	Oral cavity	OSCC	regulation of protein ubiquitination	143/7305	210/18723	1.01e-17	9.80e-16	143
GO:000989519	Oral cavity	OSCC	negative regulation of catabolic process	180/7305	320/18723	2.44e-10	6.86e-09	180
GO:19033227	Oral cavity	OSCC	positive regulation of protein modification by small protein conjugation or removal	88/7305	138/18723	3.24e-09	7.39e-08	88
GO:004217719	Oral cavity	OSCC	negative regulation of protein catabolic process	77/7305	121/18723	3.49e-08	6.64e-07	77
GO:00313986	Oral cavity	OSCC	positive regulation of protein ubiquitination	75/7305	119/18723	9.46e-08	1.65e-06	75
GO:004851116	Oral cavity	OSCC	rhythmic process	157/7305	298/18723	1.00e-06	1.36e-05	157
GO:000762316	Oral cavity	OSCC	circadian rhythm	110/7305	210/18723	5.40e-05	4.48e-04	110

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

MYCBP2

SNV

Missense_Mutation

c.8219A>T

p.Lys2740Met

p.K2740M

O75592

protein_coding

deleterious_low_confidence(0)

probably_damaging(0.99)

TCGA-A1-A0SO-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Chemotherapy

MYCBP2

SNV

Missense_Mutation

c.11849N>T

p.Trp3950Leu

p.W3950L

O75592

protein_coding

deleterious(0)

probably_damaging(0.932)

TCGA-A2-A0CP-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

MYCBP2

SNV

Missense_Mutation

rs150834693

c.9229N>G

p.Ile3077Val

p.I3077V

O75592

protein_coding

tolerated(0.57)

possibly_damaging(0.558)

TCGA-A8-A06P-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Unspecific

MYCBP2

SNV

Missense_Mutation

c.10846C>T

p.His3616Tyr

p.H3616Y

O75592

protein_coding

deleterious(0)

possibly_damaging(0.838)

TCGA-A8-A095-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

5-fluorouracil

MYCBP2

SNV

Missense_Mutation

c.11147C>T

p.Pro3716Leu

p.P3716L

O75592

protein_coding

deleterious(0.01)

probably_damaging(0.987)

TCGA-A8-A09Z-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

MYCBP2

SNV

Missense_Mutation

c.8154N>C

p.Lys2718Asn

p.K2718N

O75592

protein_coding

tolerated(0.25)

benign(0.04)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

MYCBP2

SNV

Missense_Mutation

c.7918N>C

p.Asp2640His

p.D2640H

O75592

protein_coding

deleterious(0.01)

possibly_damaging(0.674)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

MYCBP2

SNV

Missense_Mutation

c.3984N>C

p.Lys1328Asn

p.K1328N

O75592

protein_coding

deleterious(0.02)

probably_damaging(0.99)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

MYCBP2

SNV

Missense_Mutation

rs770147270

c.6037N>A

p.Glu2013Lys

p.E2013K

O75592

protein_coding

deleterious(0)

probably_damaging(0.935)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

MYCBP2

SNV

Missense_Mutation

novel

c.2920N>A

p.Val974Ile

p.V974I

O75592

protein_coding

tolerated(0.1)

possibly_damaging(0.846)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1